As artificial intelligence (AI) accelerates drug discovery, a critical legal question remains unresolved: when an AI system designs a novel drug, who is recognized as the inventor? Under current patent law, only humans can be named as inventors. This article explores the implications for the biotechnology industry in 2026 and beyond.
The Legal Landscape in 2026
Patent offices globally, including the U.S. Patent and Trademark Office (USPTO) and the European Patent Office (EPO), have consistently ruled that AI systems cannot be listed as inventors. Their rationale: inventorship requires 'conception,' a mental act exclusive to natural persons. However, as AI tools become more autonomous in generating drug candidates, this position is under increasing scrutiny.
In 2026, courts and policymakers are grappling with cases that test the boundaries of AI-assisted inventorship. For instance, in landmark rulings, courts have held that if a human significantly contributes to the AI's outputβsuch as by designing the training data or interpreting the resultsβthat human can claim inventorship. But when the AI's role is more autonomous, the patent may be invalidated.
Industry Responses and Challenges
Pharmaceutical companies, eager to protect their AI-driven discoveries, are developing strategies to ensure human involvement is documented and substantial. Some are using 'AI as a tool' frameworks, where humans guide the AI's search and validate its outputs. Others are lobbying for legislative changes to recognize AI as a co-inventor, a move that remains controversial.
Critics argue that granting AI inventorship could undermine the incentive structure of patents, which reward human ingenuity. Proponents counter that without such recognition, AI-driven innovations may go unprotected, stifling investment in this promising field.
The Future Outlook
Looking ahead, experts predict that by 2030, we may see new legal frameworks that address AI inventorship more comprehensively. Some propose a 'sui generis' system for AI-generated inventions, offering reduced patent terms but clearer ownership rules. Others call for international harmonization to avoid forum shopping.
For now, in 2026, the practical advice for researchers and companies is to maintain meticulous records of human contributions to AI-assisted discoveries. As the law evolves, those with clear documentation will be best positioned to secure patents.
Conclusion
The question of credit when AI designs a drug remains a moving target. While current law mandates human inventors, the rapid advancement of AI in biotechnology is forcing a reexamination. The outcome will shape not only the future of drug development but also the broader relationship between AI and intellectual property rights.